Shares of Large-cap health care company Edwards Lifesciences moved -1.1 this afternoon, and are now trading at $70.52 per share. On the other hand, the average analyst target price for the stock is $92.92.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
Edwards Lifesciences Investors Should Consider This:
-
Edwards Lifesciences has moved -18.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 2.87. A number between 0 and 1 could mean that the market is undervaluing Edwards Lifesciences's estimated growth potential
-
Its Price to Book (P/B) ratio is 6.72
Understanding Edwards Lifesciences's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-13 | 5,382,400 | -2,512,800 | 33 | 10.0 |
| 2022-02-14 | 5,232,500 | -2,396,800 | 30 | 0.0 |
| 2021-02-12 | 4,386,300 | -1,989,100 | 30 | 7.14 |
| 2020-02-14 | 4,348,000 | -1,994,900 | 28 | 0.0 |
| 2019-02-15 | 3,722,800 | -1,710,700 | 28 | -12.5 |
| 2018-02-16 | 3,435,300 | -1,470,800 | 32 |
Edwards Lifesciences's operating margins have averaged 30.2% over the last 6 years, which is significantly higher than the Specialty Industrial Machinery industry average of 13.8%. The firm's margins exhibit a relatively stable growth trend of 0.6%.
